Search | Clinical Trials Finder

Conditions: Leukemia, Myeloid, Monocytic
Interventions: BSMA; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Heart Failure
Interventions: Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 15
States / cities: Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more

Conditions: Stage I Squamous Cell Carcinoma of the Oropharynx, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Tongue Cancer
Interventions: questionnaire administration, quality-of-life assessment; Other · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Overweight, Obese
Interventions: Steps to Health, Steps to Health Plus!; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioblastoma
Interventions: Not listed
Lead sponsor: BPGbio; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Graft Versus Host Disease
Interventions: Natalizumab, Methylprednisolone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions: Best Practice, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Radiation Therapy; Other · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 552
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more

Conditions: Hypertension, Pulmonary
Interventions: PF-00489791, placebo, sildenafil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Phoenix, Arizona • Gainesville, Florida • Omaha, Nebraska + 2 more

Conditions: Hiv, HIV Infections, AIDS
Interventions: Stigma Reduction Intervention; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 99 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Depression, End Stage Renal Disease
Interventions: Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: Tacere Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lymphoma
Interventions: rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 29
States / cities: Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more

Conditions: Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
Interventions: contrast-enhanced magnetic resonance imaging; Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Oligometastatic Prostate Cancer (OMPC)
Interventions: AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 39
States / cities: Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma
Interventions: Magnetic Resonance Imaging, Mammogram, Ultrasound, Ultrasound-Guided Biopsy, Twinkle marker; Procedure · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Nicotine Dependence
Interventions: Placebo, Varenicline; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 140
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more

Conditions: HEAD & NECK Cancer
Interventions: RAD001 + docetaxel + cisplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: CML, Chronic Phase, CML (Chronic Myelogenous Leukemia, CML - Philadelphia Chromosome, Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
Interventions: Bosutinib, Dasatinib, Imatinib, Nilotinib; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cystic Fibrosis
Interventions: Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 2 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more

Conditions: Low Back Pain
Interventions: Core Stabilization, Trunk Motion and Fitness; Other
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • West Chester, Pennsylvania

Conditions: Chronic Kidney Diseases
Interventions: CLBS201; Drug
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy, Presbyopia, Myopia, Dementia
Interventions: Ocufolin; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Physical Activity as Self-Management Approach to Improve Health Outcomes in AML

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer

Steps to Health: Targeting Obesity in the Health Care Workplace

Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

Standardized Patients to Measure and Address Intersectional Stigma

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer

Effects of Chantix on Relapse Prevention for Smoking Cessation

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Recurrent Low Back Pain: Linking Mechanism to Outcomes (RCT)

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

Clinical Applications of Advanced Ophthalmic Imaging